Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is a strong performer in the health care industry, as shown by its projected MA rate increase and partnerships with major payers resulting in revenue growth. Its utilization of technology and data analytics to provide value-based care and recent acquisition of Prospect Medical indicate potential for further growth. Comparison to a similar company, EVH, suggests ASTH may also have good cost control measures.

Bears say

Astrana Health is facing several challenges that could negatively impact its performance and stock price. These include declining enrollment in both Medicaid and Exchange segments, tighter eligibility regulations, and margin pressure. The company has also faced volatility in its segment reporting and reserves. While Astrana Health has a healthy cash flow, a strong balance sheet, and potential synergies with its recent acquisition, there is uncertainty around its claims visibility and reserve adequacy. Additionally, the company operates in a highly regulated industry with potential reimbursement and regulatory pressures. These risks, combined with the company's high valuation, make it a risky investment option.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.